Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Laura Daugherty

Nurse Practitioner, Gerontology Indianapolis, IN Nurse Practitioner

NPI 1245854819 CMS profile 10863356

8075 N Shadeland Ave Ste 310, Indianapolis, IN 46201

Open in the dashboard

General payments

$1,374

59 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Laura Daugherty of Indianapolis, IN is reported in the CMS Open Payments database as having received $1,374 across 59 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $418 19
2023 General $655 26
2022 General $229 10
2021 General $73 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laura Daugherty
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Laura Daugherty were reported at $0. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Laura Daugherty Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $73 $133 $44–$396 $132
2022 $229 $142 $48–$452 $149
2023 $655 $158 $53–$482 $160
2024 $418 $171 $55–$533 $164
2025 $0 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Actelion Pharmaceuticals US, Inc. $361 13 payments
  2. Abbott Laboratories $167 1 payment
  3. Pfizer Inc. $115 7 payments
  4. Merck Sharp & Dohme Corporation $104 6 payments
  5. Janssen Pharmaceuticals, Inc $92 5 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $86 5 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $81 1 payment
  8. AstraZeneca Pharmaceuticals LP $73 4 payments
  9. United Therapeutics Corporation $58 3 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $47 3 payments
  11. Other $190 11 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $1,186 57 payments
  2. Education $189 2 payments
Products named General payments · program years 2021–2024
  1. OPSUMIT $334 11 payments
  2. UPTRAVI $332 11 payments
  3. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $167 1 payment
  4. VERQUVO $99 7 payments
  5. XARELTO $92 5 payments
  6. NURTEC ODT $81 1 payment
  7. VYNDAQEL $76 5 payments
  8. JARDIANCE $68 4 payments
  9. PAXLOVID $68 4 payments
  10. REMODULIN $58 3 payments
  11. Other $490 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

452

Median for Nurse Practitioner: 389

Drug cost

$2,033,981

Median for Nurse Practitioner: $21,885

Branded share of claims

37.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opsumit Macitentan Brand 73 $916,439
Orenitram Er Treprostinil Diolamine Brand 42 $400,274
Uptravi Selexipag Brand 15 $336,049
Adempas Riociguat Brand 22 $307,566
Ambrisentan Generic 27 $45,391
Tadalafil Generic 85 $21,584
Potassium Chloride Generic 84 $2,526
Sildenafil Citrate Generic 12 $1,647
Torsemide Generic 49 $1,531
Klor-Con M20 Potassium Chloride Brand 18 $876

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $58
$58 73 —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $58
$58 15 —
INJECTAFER
  • Daiichi Sankyo Inc. $28
$28 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $27
$27 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

59 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record